Cyclopharm Limited (CYC) AI Stock Analysis

• Market Cap: AU$70.02M
• Dividend Yield: N/A
• Average Volume (3M): 97.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: 34.20%
• EPS Growth: -23.90%
• Country: AU
• Employees: 95
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.07
• Shares Outstanding: 111,136,850
• 10 Day Avg. Volume: 155,345
• 30 Day Avg. Volume: 97,642
• PEG Ratio: -0.08
• Price to Book (P/B): 3.83
• Price to Sales (P/S): 5.93
• P/FCF Ratio: -12.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: AU$0.97 ▲(0.21% Upside)

The overall stock score of 50.4 reflects significant financial challenges, including persistent losses and negative cash flows, which are major concerns. While technical indicators show some bullish momentum, the stock's valuation is unattractive due to its negative P/E ratio. The strong equity position provides some stability, but the lack of profitability remains a critical issue.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a stable demand for Cyclopharm's products, suggesting a solid market position and potential for future expansion.

Strong Equity Position

A strong equity position with low leverage provides financial stability and flexibility, allowing the company to invest in growth opportunities.

Market Position in Healthcare

Operating in the healthcare sector with innovative imaging technologies positions Cyclopharm well for long-term growth, given the increasing demand for advanced medical diagnostics.

Negative Factors

Lack of Profitability

Persistent lack of profitability and negative margins indicate challenges in operational efficiency, which could hinder long-term financial health and growth.

Negative Cash Flow

Negative cash flow highlights difficulties in sustaining operations through internal cash generation, potentially limiting investment in growth initiatives.

Financial Challenges

Ongoing financial challenges, including losses and negative cash flows, pose risks to Cyclopharm's ability to maintain operations and invest in future growth.

Cyclopharm Limited Business Overview & Revenue Model

Company Description

Cyclopharm Limited (CYC) is a biotechnology company focused on developing and commercializing innovative diagnostic imaging products, particularly in the field of nuclear medicine. The company specializes in radiopharmaceuticals, with core products including Technegas, a radiopharmaceutical used for lung ventilation imaging. Cyclopharm operates primarily in the healthcare sector, aiming to enhance patient outcomes through advanced imaging technologies.

How the Company Makes Money

Cyclopharm generates revenue primarily through the sale of its radiopharmaceutical products, particularly Technegas, which is utilized in various diagnostic imaging procedures. The company also earns money through licensing agreements and partnerships with healthcare institutions and distributors who facilitate the delivery of its products to hospitals and clinics. Additionally, Cyclopharm may benefit from collaborations with research institutions and pharmaceutical companies that seek to utilize its technology for clinical trials or new product development. Grant funding and government support for research and development activities also contribute to the company's earnings.

Cyclopharm Limited Financial Statement Overview

Summary

Cyclopharm Limited is facing significant financial challenges with consistent losses and negative cash flows, despite some revenue growth. The company's strong equity position provides some financial stability, but the lack of profitability and cash flow generation poses substantial risks to its financial health.

Income Statement

Cyclopharm Limited has shown consistent growth in revenue over the years, with a revenue growth rate of 1.6% from 2023 to 2024. However, the company is struggling with profitability, evidenced by persistent negative EBIT and net income, resulting in negative profit margins. Despite some growth in gross profit, the absence of positive net income and EBIT indicates significant challenges in operational efficiency and profitability.

Balance Sheet

The balance sheet shows a relatively strong equity position with a Debt-to-Equity ratio of 0.19, indicating low leverage. The equity ratio stands at 68.8%, reflecting financial stability and a cushion against liabilities. However, the company has been consistently reporting net losses, impacting the return on equity negatively.

Cash Flow

Cyclopharm Limited's cash flow statement reveals ongoing challenges in generating positive cash flow, with a negative operating cash flow and free cash flow in 2024. The free cash flow growth rate and operating cash flow to net income ratio are concerning, indicating difficulties in sustaining operations through internal cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.79M	27.57M	26.34M	23.22M	17.70M	14.68M
Gross Profit	18.36M	17.93M	16.08M	5.94M	3.20M	2.08M
EBITDA	-14.93M	-13.69M	-3.84M	-6.47M	-5.79M	-7.73M
Net Income	-13.38M	-13.20M	-4.70M	-6.61M	-5.04M	-6.04M
Balance Sheet
Total Assets	55.91M	62.13M	45.91M	49.54M	55.74M	28.28M
Cash, Cash Equivalents and Short-Term Investments	12.41M	20.57M	11.73M	20.30M	29.25M	1.87M
Total Debt	7.98M	8.29M	4.23M	4.33M	4.51M	4.71M
Total Liabilities	19.81M	19.40M	13.65M	13.01M	12.67M	11.16M
Stockholders Equity	36.10M	42.73M	32.26M	36.54M	43.07M	17.12M
Cash Flow
Free Cash Flow	-14.36M	-13.55M	-7.74M	-8.21M	-2.79M	-9.47M
Operating Cash Flow	-13.71M	-12.57M	-7.20M	-6.66M	-1.63M	-8.93M
Investing Cash Flow	-804.71K	-971.86K	-508.47K	-1.55M	-1.16M	-874.19K
Financing Cash Flow	-967.63K	22.22M	-1.02M	-725.64K	30.17M	-985.96K

Cyclopharm Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYC, the sentiment is Positive. The current price of 0.97 is above the 20-day moving average (MA) of 0.70, above the 50-day MA of 0.72, and below the 200-day MA of 1.02, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 69.73 is Neutral, neither overbought nor oversold. The STOCH value of 55.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CYC.

Cyclopharm Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CYC	50 Neutral	AU$70.02M	-5.38	-31.98%	―	34.20%	-23.90%
CMP	50 Neutral	AU$61.51M	-46.38	-6.35%	―	2.23%	-263.16%
ARX	49 Neutral	AU$274.30M	-78.71	-2.01%	―	16.93%	76.47%
IPD	48 Neutral	AU$73.35M	―	-74.00%	―	23.31%	-17.35%
4DX	47 Neutral	AU$830.45M	-22.71	-44.49%	―	55.91%	22.60%
EMV	44 Neutral	AU$176.12M	-16.52	-70.55%	―	―	-257.32%

Cyclopharm Limited Corporate Events

Cyclopharm Partners with Western University to Advance Asthma Detection

Cyclopharm Limited has partnered with Western University in Canada to explore the use of its Technegas® technology in detecting mild to moderate asthma in young adults. The clinical trial, led by Professor Grace Parraga, aims to determine if Technegas® can identify hidden lung ventilation issues in asthma patients, potentially changing clinical practices and expanding the use of Technegas® beyond its current applications. This research aligns with Cyclopharm’s strategy to broaden the clinical use of Technegas® and represents a significant growth opportunity for the company.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Sells Cyclotron Asset to Focus on Technegas® Expansion

Cyclopharm Limited has completed the sale of its non-core Cyclotron asset for $6.2 million, enhancing its balance sheet and aligning with its strategic focus on expanding the Technegas® business globally. The transaction provides financial flexibility to accelerate Technegas® commercial growth, and Cyclopharm continues to explore collaborative opportunities with Cyclotek to enhance patient access to advanced nuclear medicine solutions.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited to Host Webinar on 1H 2025 Results and Future Prospects

Cyclopharm Limited announced a webinar to discuss its half-year results, U.S. commercialization progress, and future clinical opportunities for Technegas. This event reflects the company’s ongoing efforts to expand its market presence and enhance its product’s applications, potentially impacting its industry positioning and stakeholder interests.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Achieves Record Revenue and Expands U.S. Market Presence

Cyclopharm Limited reported record half-year revenue growth, driven by strong commercial traction in the USA and strategic milestones that enhance its position as a leader in functional lung imaging. The company achieved a 26% increase in revenue, with significant contributions from Technegas® sales in the USA and third-party distribution. Cyclopharm secured a U.S. patent extension, ensuring exclusivity until 2031, and filed a new IP family for Technegas® generator innovations. The company’s U.S. market momentum is supported by installations in strategic centers and contracts with major hospital groups, while clinical validation continues to expand Technegas® applications beyond pulmonary embolism. Cyclopharm is poised for accelerated growth and aims for 250-300 U.S. installations by the second half of 2026.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

Cyclopharm Limited Reports Revenue Growth Amid Increased Losses

Cyclopharm Limited reported a 26% increase in revenues from ordinary activities for the half-year ended 30 June 2025, reaching $15,422,971. Despite the revenue growth, the company experienced a 2% increase in its loss after tax, amounting to $7,687,875. The announcement highlights the company’s financial performance, indicating a challenging period with higher losses despite increased revenue, which may impact its market positioning and stakeholder confidence.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.